Literature DB >> 2961056

Erythrocyte CR1 (C3b/C4b receptor) levels and disease activity in patients with SLE.

B S Thomsen1, H Nielsen, V Andersen.   

Abstract

Fifty-four patients with systemic lupus erythematosus (SLE) were examined for (1) CR1 (C3b/C4b receptor) levels on erythrocytes by an enzyme-linked immunosorbent assay, (2) levels of circulating immune complexes (IC) by a polyethylene glycol precipitation complement consumption method, and (3) concentrations of C3d split products in plasma by intermediate gel rocket immunoelectrophoresis. A preponderance of low CR1 levels was found among patients with SLE (mean 40%, range 13-106) as compared with normal controls (mean 70%, range 24-130) (p less than 0.001). The concentrations of circulating IC were elevated in 38% of 58 samples. The concentrations of C3d were elevated in 72%, and were positively correlated with the levels of IC (tau = 0.28; p less than 0.005) and with disease activity as assessed by a modification of the UCH/Middlesex criteria. Negative correlations were seen between the CR1 numbers and disease activity (p = 0.01), concentrations of circulating IC (tau = -0.14; p less than 0.005), and C3d (tau = -0.21; p less than 0.005). The changes found in CR1 levels on repeated study were, however, relatively small (less than or equal to 27%; median 5), even during periods of changing disease activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2961056     DOI: 10.3109/03009748709102505

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  5 in total

1.  Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare.

Authors:  D J Birmingham; K F Gavit; S M McCarty; C Y Yu; B H Rovin; H N Nagaraja; L A Hebert
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

2.  Distribution of the HindIII restriction fragment length polymorphism among patients with systemic lupus erythematosus with different concentrations of CR1.

Authors:  H Satoh; E Yokota; K Tokiyama; T Kawaguchi; Y Niho
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

3.  Evaluation of in vivo immune complex formation and complement activation in patients receiving intravenous streptokinase.

Authors:  J Freysdottir; S Ormarsdottir; A Sigfusson
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

4.  A long-term immunological study of childhood onset systemic lupus erythematosus.

Authors:  C K Ting; K H Hsieh
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

5.  Peripheral catabolism of CR1 (the C3b receptor, CD35) on erythrocytes from healthy individuals and patients with systemic lupus erythematosus (SLE).

Authors:  J H Cohen; H U Lutz; J L Pennaforte; A Bouchard; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.